Chemically defined, BalanCD HEK293 Viral Feed enhances viral vector production for gene therapy applications and viral vector-based vaccines
FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies
MADISON, WIS., January 5, 2023 -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases.
Investment will Accelerate Development of New High-Content Screening Assay Services Using Differentiated iPSCs
TOKYO, November 22, 2022 – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.
FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer
MADISON, Wis., September 15, 2022 -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today announces the appointment of Ilyas Singeç, M.D., as chief scientific officer effective September 12. In this newly created strategic role, Dr. Singeç will define the Company’s future iPSC technological pipeline.
FUJIFILM Diosynth Biotechnologies Breaks Ground on Large-Scale Microbial Manufacturing Facility Expansion in Billingham, UK
BILLINGHAM, UNITED KINGDOM, September 22, 2022 – FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, announced today the start of the expansion of its large-scale microbial manufacturing facility located at the Billingham, UK campus. The company held a small internal ceremony at the site on 6 September 2022.
FUJIFILM Diosynth Biotechnologies breaks ground on a USD 1.6 billion (11 billion Danish kroner) expansion in Hillerød, Denmark
Hillerød, Denmark, September 12, 2022 - FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, held a groundbreaking ceremony today to celebrate the start of its new expansion project to transform the Denmark site into the largest end-to-end CDMO in Europe.
FUJIFILM Irvine Scientific Launches Heavy Oil for Embryo Culture: Optimized Protection for the IVF Laboratory
Offering ideal handling viscosity with added confidence from rigorous testing procedures
SANTA ANA, Calif., July 26, 2022-- FUJIFILM Irvine Scientific, Inc., a world leader in the innovation, development, and manufacture of cell culture media and assisted reproductive technologies (ART), today announced the launch of its Heavy Oil for Embryo Culture, a sterile mineral oil with an optimal weight viscosity that provides the ideal balance between ease of use and protection.
Fujifilm to Invest USD 1.6 billion to enhance and expand its global offering of cell culture manufacturing services
TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced the investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, and world-leading contract development and manufacturing organization (CDMO). This investment will enhance FUJIFILM Diosynth Biotechnologies’ sites in Hillerød, Denmark, and Texas in the United States.
Annual program aims to advance translational medical science research and education
The Company looks to expand the use of AI in efforts to improve IVF success
Fujifilm Life Sciences Showcases its Comprehensive Solutions to Support Advanced Therapies at BIO2022
Fujifilm-sponsored educational session to spotlight microbiome therapeutics development innovation
Cambridge, Mass. – Fujifilm Life Sciences, a portfolio of companies with comprehensive solutions ranging from Bio CDMO services to drug development support, and including induced pluripotent stem cells (iPSCs), cell culture media, and reagents, today announced that it will have a unified presence at BIO2022 (June 13-16) at the San Diego Convention Center in San Diego, California.
Fujifilm Begins U.S. Clinical Phase 2a Study of FF-10832 in Combination with KEYTRUDA® (pembrolizumab, Merck & Co., Inc., Rahway, N.J., U.S.A.) for Patients with Advanced Solid Tumors
TOKYO ― FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has begun implementation of a phase 2a study in the U.S. to evaluate safety, tolerability, and preliminary efficacy of FF-10832, a liposomal drug candidate, in combination therapy with Merck & Co., Inc., Rahway, N.J., U.S.A.’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for patients with advanced solid tumors.
FUJIFILM Cellular Dynamics Launches Parkinson’s Disease iCell DopaNeurons featuring LRRK2 and GBA Mutations
Leverages iPSCs derived from participants in The Michael J. Fox Foundation for Parkinson’s Research’s landmark study, PPMI
Chimeron Bio Enters Into Manufacturing Agreement With FUJIFILM Diosynth Biotechnologies to Advance its RNA Oncology Candidates
Philadelphia, PA and College Station, TX - Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, today announced it has entered into a manufacturing agreement with FUJIFILM Diosynth Biotechnologies (FDB), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, to advance the Company’s Oncology portfolio
Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
Facility acquisition includes 134 employees in manufacturing and quality positions
TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for life science research, bioproduction, and cell therapy manufacturing, completed the acquisition of Shenandoah Biotechnology, Inc., a leading manufacturer of recombinant proteins. Terms of the deal were not disclosed.
Acquisition offers customers worldwide a single point of access for cGMP cell culture solutions for biopharmaceuticals, and cell and gene therapies
FUJIFILM Diosynth Biotechnologies Gifts $200,000 to Wake Tech Foundation to Establish Early College Suite
Research Triangle Park, N.C., – FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, today announces a $200,000 contribution to the Wake Tech Foundation to establish the FUJIFILM Diosynth Biotechnologies Early College Suite.
Promega Corporation and FUJIFILM Cellular Dynamics Announce Strategic Collaboration to Advance Novel Assay Development
New licensing agreement will deliver luminescent reporter technology into iPSCs
Fujifilm launches life sciences strategic investment fund focused on emerging companies with high impact biotechnology
TOKYO – FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) announces the launch of its life sciences strategic investment fund managed by the Life Sciences Corporate Venture Capital (LS-CVC), a newly established group within the Fujifilm’s Life Sciences Strategy Headquarters in Tokyo. Fujifilm is initially investing 7B¥ (about 60 million USD ) to start the fund, targeting cutting-edge biotechnology primarily through partnerships with early-stage companies around the world.
Fujifilm Expands its Advanced Therapies CDMO Business with the Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc.
TOKYO, — FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Located in Thousand Oaks, California, the facility is readily expandable with the flexibility to produce both clinical and commercial cell therapies including allogeneic T-cell and CAR T immunotherapies.
FUJIFILM Cellular Dynamics and PhenoVista Biosciences Announce Strategic Alliance to Improve the Drug Discovery Process
MADISON, Wis., and SAN – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) technologies, and PhenoVista Biosciences (PhenoVista), a top provider of custom imaging-based phenotypic assay services, today announce a strategic alliance to improve the drug discovery process, by using iPSCs in screening.
Expands the sites’ Process Development, Process Characterization and Analytical Services and adds approximately 145 skilled positions by 2024
Fujifilm Also Congratulates the 2021 Fellowship Recipients
CAMBRIDGE, Mass. — FUJIFILM Holdings America Corporation (Fujifilm), today announced that it has renewed its commitment to the Fujifilm Fellowship fund at Harvard Medical School (HMS) to advance education and research in the field of translational medicine, the process of applying basic research in the laboratory for new therapeutic development. The gift will support up to 8 additional Ph.D. candidates at HMS through 2024.
FUJIFILM Diosynth Biotechnologies to Increase Advanced Therapy and Vaccine Production Capacity with New $300 Million Facility in Texas
The Texas site is the largest single-use CDMO production campus in North America
Adds approximately 150 skilled positions to the site by 2024 and is supported by the State of Texas through a $1.5 million Enterprise Fund Award
Fujifilm Kicks Off Operations at its New, State-of-the-Art Cell Culture Media Manufacturing Facility in Europe
-Expanding cell culture media production capacity to meet the increasing demand for biopharmaceuticals
-Enhancing global production structure with modern manufacturing sites in Japan, the U.S. and Europe
FUJIFILM Diosynth Biotechnologies confirms £400 million investment plans to create the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom
BILLINGHAM, UK, ― FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organisation (CDMO) for biologics, viral vaccines and viral vectors, has confirmed a £400 million planned investment package at its UK facility in Billingham, Teesside. This investment package more than doubles the site’s existing development and manufacturing footprint, creating the largest multi-modal biopharmaceutical manufacturing site in the United Kingdom1 and is expected to create up to 350 highly-skilled jobs.
New center brings local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development
SANTA ANA, California: FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced the establishment of an Innovation and Collaboration Center in Suzhou New District, China.
FUJIFILM DIOSYNTH BIOTECHNOLGOGIES BREAKS GROUND ON THE LARGEST CELL CULTURE BIOPHARMACEUTICAL CDMO FACILITY IN NORTH AMERICA
The new, state-of-the-art facility will be located in Holly Springs, North Carolina
New European hub in Tilburg, the Netherlands, scheduled to open late 2021
BlueRock Therapeutics, FUJIFILM Cellular Dynamics, and Opsis Therapeutics Enter into a Strategic R&D Alliance to Discover and Develop Cell Therapies for Eye Diseases
Cambridge, Mass., and Madison, Wis. – BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, FUJIFILM Cellular Dynamics, Inc.
Innovation and growth remain a priority to support customers and COVID-19 initiatives
SANTA ANA, California - FUJIFILM Irvine Scientific, Inc. is celebrating its 50th year of providing innovative cell culture media products and services. Since its formation, the Company has established a reputation as an innovator and leader in providing cell culture solutions for the Life Science and Medical markets.
Fujifilm Selects North Carolina as the Location to Build the Largest Cell Culture Biopharmaceutical CDMO Facility in North America
Fujifilm to invest $2 Billion and create 725 jobs with its new state-of-the-art large-scale cell culture manufacturing facility in Holly Springs, North Carolina
TOKYO ― FUJIFILM Corporation (President: Kenji Sukeno) has announced the selection of Holly Springs, North Carolina as the location for its new large-scale cell culture production site in the United States.
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
MADISON, Wis. and SEATTLE - FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, and Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, announced today that Sana has been granted a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development of commercial cell therapies.
Signing a business partnership agreement on the contract development and manufacturing of regenerative medicine products
TOKYO – FUJIFILM Corporation (President: Kenji Sukeno) announces that it signed an agreement today to invest 100 million yen into a biotech venture, Cuorips Inc. through underwriting its third-party allocation of shares. Cuorips is a biotech venture for developing and commercializing iPSC-based treatment for heart failure.
Fujifilm and the Center for Advanced Biological Innovation and Manufacturing Announce $76M in Funding for Manufacturing and Innovation Center
Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
End-to-End Single-Site Solution from Drug Substances to Fill-Finish & Packaging
TOKYO ― FUJIFILM Corporation (President: Kenji Sukeno) is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
STEVE BAGSHAW, NON-EXECUTIVE CHAIRMAN OF FUJFILM DIOSYNTH BIOTECHNOLGIES RECOGNIZED IN NEW YEARS HONORS LIST 2021
Billingham, United Kingdom – FUJIFILM Diosynth Biotechnologies, is pleased to share that Steve Bagshaw, non-executive chairman of FUJIFILM Diosynth Biotechnologies, has been awarded Commander of the Most Excellent Order of the British Empire (CBE) for Services to the U.K. Manufacturing and Biotechnology Sector in the New Years Honors List 2021.
Fujifilm to invest $40 Million to Establish a New State-of-the-Art Viral Vector and Advanced Therapy Process Development and Manufacturing Facility
Establishing a presence in Massachusetts within the academia and pharma communities to perform cutting-edge research and innovation in the field of advanced therapies.
CAMBRIDGE, Mass - FUJIFILM Holdings America Corporation (Fujifilm), announced that five new recipients have been awarded the Fujifilm Fellowship at Harvard Medical School (HMS). Since its launch in 2019, the program has provided 11 fellowships for Ph.D. students who are enrolled at HMS, and focused on translational medicine, the process of applying basic research in the laboratory for new therapeutic development.
Fujifilm Partners with Chinese Pharmaceutical Company Carelink in Deploying Anti-influenza Drug Avigan® Tablets in China
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) has announced that the company has partnered with Chinese pharmaceutical company Carelink Pharmaceutical Co., Ltd. (hereinafter “Carelink”) in deploying anti-influenza drug Avigan® Tablets (generic name: favipiravir,“Avigan”) in China. Going forward, through a future application and approval of Avigan for imported drug registration, to be submitted by Carelink, FUJIFILM Toyama Chemical aims to introduce Avigan to the Chinese market.
Fujifilm Filed an Application for Partial Changes to the Manufacturing and Marketing Approval Matters of Anti-Influenza Drug Avigan® Tablet in Japan to Include Additional Indication for COVID-19
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced that the company filed an Application for Partial Changes to manufacturing and marketing approval matters of its anti-influenza drug Avigan® Tablet (generic name: favipiravir,”Avigan”) to the Ministry of Health, Labour and Welfare in Japan. The filing seeks to add an indication and other items relating to novel coronavirus infections (hereinafter “COVID-19”).
FUJIFILM Diosynth Biotechnologies Stands Ready to Manufacture Lilly COVID-19 Antibody for Low- and Middle-Income Countries
HILLERØD, Denmark - FUJIFILM Diosynth Biotechnologies, a world leading Contract Development and Manufacturing Organization (CDMO) for biologics, viral vaccines and viral vectors, today announced that it will manufacture Eli Lilly and Company’s COVID-19 therapeutic antibody at its GMP1 facility in Hillerød, Denmark, deploying capacity reserved for the COVID-19 Therapeutics Accelerator.
Axxam and FUJIFILM Cellular Dynamics announce strategic alliance to deliver integrated hiPSC drug discovery solutions
MILAN (Italy) and MADISON (Wis., USA) – Axxam S.p.A., a leading provider of integrated drug discovery services across life sciences industries, and FUJIFILM Cellular Dynamics, Inc., a leading developer and manufacturer of human induced pluripotent stem cell (hiPSC) models and therapies, announce a strategic alliance to improve the drug discovery process.
TOKYO - FUJIFILM Corporation (President: Kenji Sukeno) is expanding its gene therapy offering, with the addition of viral vector process development and GMP1 manufacturing services at FUJIFILM Diosynth Biotechnologies’ in the North East of the United Kingdom (UK).
Fujifilm Concludes a Manufacturing Contract Agreement with VLP Therapeutics, for a COVID-19 Vaccine Formulation
-Process development and manufacture of formulations using lipid nanoparticles Drug Delivery System technology-
TOKYO—FUJIFILM Corporation (President: Kenji Sukeno) announces the conclusion of a manufacturing contract agreement with biotechnology company, VLP Therapeutics Japan LLC (Representative Executor: Wataru Akahata, hereinafter “VLP Therapeutics”) regarding COVID-19 vaccine formulation developed by VLP Therapeutics.
Centus Biotherapeutics Receives European Marketing Authorization for Equidacent®, Biosimilar Avastin®
LONDON and TOKYO ― Centus Biotherapeutics Ltd., a joint venture between Fujifilm Kyowa Kirin Biologics Co., Ltd. and AstraZeneca, today announced that the European Commission (EC) has granted the marketing authorization for Equidacent® (Product Code: FKB238), the company’s biosimilar to Avastin® (bevacizumab).
Anti-influenza drug Avigan® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 patients
TOKYO — FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter “FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of “Avigan Tablet” (generic name: favipiravir, “Avigan”) conducted in Japan for patients with novel coronavirus infections (hereinafter “COVID-19”). The efficacy primary endpoint is time to negative conversion of detectable SARS-CoV 2 viral RNA in the RT-PCR assays, and to alleviation of symptoms (body temperature, oxygen saturation and chest images).